Fundraising Fox
Novus Therapeutics
1 known investors
Find your way into Novus Therapeutics
Sign up to see every warm intro you have to Novus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Novus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eledon develops tegoprubart, an anti-CD40L antibody immunosuppressant for organ transplant recipients, aimed at preventing transplant rejection and extending organ longevity. The company is conducting clinical trials in kidney transplantation with expansion into liver transplants and xenotransplantation.
Founders & leadership
SP
Steven PerrinPresident and Chief Scientific Officer
Investors · 1
Frequently asked questions
- What does Novus Therapeutics do?
- Eledon develops tegoprubart, an anti-CD40L antibody immunosuppressant for organ transplant recipients, aimed at preventing transplant rejection and extending organ longevity. The company is conducting clinical trials in kidney transplantation with expansion into liver transplants and xenotransplantation.
- Who are Novus Therapeutics's investors?
- Novus Therapeutics's investors include Ridgeback Capital.